• Join Abivax for a Key Opinion Leader (KOL) Investor Webcast featuring renowned gastroenterologist Professor David T. Rubin, MD from The University of Chicago, who will provide…
    Join Humacyte in-person or virtually for an investor event featuring vascular surgery key opinion leaders (KOLs) Michael Curi, MD, MPA (Rutgers…
  • Join Milestone Pharmaceuticals in-person or virtually for a Commercial Launch Plan investor event in New York to provide an overview…
    Please join Nektar Therapeutics for a virtual investor and analyst event to discuss the Type 1 Diabetes Mellitus (T1D) treatment…
    Join MeiraGTx for an investor webcast featuring key opinion leader (KOL) Professor Michel Michaelides, Consultant Ophthalmologist at Moorfields Eye Hospital, who will…
    Join UroGen Pharma for an investor webcast with members of the company’s leadership team, who will discuss UroGen's long-term growth…
    Join Volition for a virtual investor event, featuring Volition company management Dr. Andrew Retter, Chief Medical Officer, and Gael Forterre,…
    INmune Bio reports the results of a double-blinded, randomized, placebo-controlled pivotal trial, known as “MissionEB,” investigating CORDStrom for treatment of…
    Join Protagonist Therapeutics for an in-person and virtual investor event providing key opinion leader (KOL) insights from Andrew Kuykendall, MD (Moffitt…
  • Join Opthea, a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related…
    Join NeuroPace in-person or virtually for an Investor Day with presentations by management focused on the Company’s vision for its…
    Join SAB BIO for a Research and Development webinar on January 28, 2025 to discuss the topline data for Phase…
    Join Adagene for a virtual KOL event featuring Aurélien Marabelle, MD, PhD (University of Paris Saclay), Daneng Li, MD (City of…
    Join MediWound for a virtual Key Opinion Leader (KOL) event to discuss EscharEx®, an innovative treatment in late-stage clinical development for…
    Join ACELYRIN for a virtual investor event to provide updated Phase 2 data for subcutaneous lonigutamab further supporting its potential…